Leading UK health scientists and institutions will provide insight into successful university spinouts, digital health in the NHS, successful Japan-UK research and commercialisation projects, and academic-industry collaborations.
Dr Jorg Taubel and Dr Ulrike Lorch will be in attendance at this one-day event and presenting to the delegation.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
